PTEN and prostate carcinoma: In mouse xenograft models of breast cancer or prostate cancer that harbors PI3K or PTEN mutation, respectively, combining the use of IKE and the rapalog CCI-779 led to substantial regression of established tumors (Yi et al., 2020).